DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,270,723 | -58.2% | 110,069 | -53.3% | 0.01% | -72.7% |
| Q1 2023 | $5,429,652 | +1224.3% | 235,662 | +1663.3% | 0.02% | +1000.0% |
| Q3 2022 | $410,000 | -63.0% | 13,365 | -61.2% | 0.00% | -60.0% |
| Q1 2022 | $1,108,000 | +27.6% | 34,435 | +100.2% | 0.01% | +150.0% |
| Q3 2021 | $868,000 | -39.7% | 17,200 | -6.3% | 0.00% | -60.0% |
| Q2 2021 | $1,439,000 | +373.4% | 18,350 | +244.4% | 0.01% | +150.0% |
| Q1 2021 | $304,000 | -41.1% | 5,328 | -63.0% | 0.00% | -71.4% |
| Q3 2020 | $516,000 | +80.4% | 14,411 | -22.8% | 0.01% | +133.3% |
| Q3 2019 | $286,000 | -55.5% | 18,657 | -39.7% | 0.00% | -50.0% |
| Q2 2019 | $642,000 | -73.7% | 30,936 | -70.6% | 0.01% | -76.9% |
| Q1 2019 | $2,441,000 | – | 105,140 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |